Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Protocol of End-PSCI trial: a multicenter, randomized controlled trial to evaluate the effects of DL-3-n-butylphthalide on delayed-onset post stroke cognitive impairment

Fig. 2

Schedule of End-PSCI. This is the schedule of End-PSCI trial. After enrolment and allocation, general information will be recorded at baseline. The treatment of standard medical therapy and standard medical therapy combined NBP treatment will last for 24 weeks after stroke. For every follow-up visit (baseline, 6 weeks, 12 weeks and 24 weeks after stroke), vital signs and medical history, application of study drugs, application of combined drugs, NHISS and MRS scores, a set of validated cognitive tests, blood samples collection and adverse events record will be implemented. Carotid Doppler ultrasonography and brain MRI including T1, T2 and T2 Fluid-attenuated inversion recovery imaging will also be performed at baseline and 24 weeks after stroke. NHISS: National Institutes of Health Stroke Scale; MRS: Modified Rankin Scale; MRI: Magnetic Resonance Imaging; FLAIR: axial fluid-attenuated inversion recovery

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us